ZERO ® – ADVANCED PROSTATE CANCER NEWS
WINTER 2023/2024
A MESSAGE FROM DR. ALICIA MORGANS (cont. from page 1)
Latest Data to Individualize Treatment in Prostate Cancer. This activity included a treatment decision-making tool for providers and now features a treatment decision-making tool for patients who have advanced prostate cancer. Patients can input information about their prostate cancer diagnosis and will be provided with the opinions of five different prostate cancer experts on a recommended treatment path. I was happy to serve as one of the five clinicians providing recommendations for this project. Tools like these incorporate guideline based care into expert experience and opinion to give patients more information and insight into the management of their own care. In closing, I wanted to remind you of all of the support resources that ZERO offers. The ZERO360 patient helpline supported an average of 142 callers each month in 2023 and provides personalized case management, assisting with everything from insurance questions to psychosocial services. The MENtor program provides one-on-one support and you can sign up to become a MENtor for someone else, or be paired with a MENtor for yourself. The ZERO Us TOO Support Groups offer peer-to-peer networking opportunities for everyone impacted by prostate cancer. More than 15 new groups were added in the fall alone! Last, but certainly not least, please consider registering now for the annual ZERO Prostate Cancer Summit, coming up in-person February 25–27, 2024 and virtually March 12–14, 2024. Please make sure you are there to lend your voice and play a part in the change that we need to see for patients and their families. Learn more about all of these programs and events at ZERO’s newly designed website, www.zerocancer.org . Thank you for being a part of the ZERO family. I am wishing you and your family good health as we begin 2024. Dr. Alicia Morgans
2023 FDA APPROVALS IN PROSTATE CANCER
New Patient Treatment Decision Tool ZERO partnered with Clinical Care Options to develop a Treatment Decision-Making Tool for advanced prostate cancer patients. Enter information about your prostate cancer diagnosis and see treatment path recommendations from five prostate cancer specialists. Check the patient tool out today! In August the FDA approved the fixed dose combination of niraparib and abiraterone acetate (Akeega) , with prednisone, for adult patients with deleterious or suspected deleterious BRCA-mutated mCRPC, as determined by an FDA-approved test. Diagnostics – Radiopharmaceutical In May the FDA approved flotufolastat F 18 injection (Posluma) for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA)–positive lesions in men with prostate cancer with suspected metastasis who are eligible for initial definitive therapy or with suspected recurrence based on elevated PSA level. This adds to our arsenal of PSMA PET imaging agents for prostate cancer. Hormone Therapy In November, the FDA approved enzalutamide (Xtandi) for non-metastatic castration-sensitive prostate cancer (nmCSPC) patients with biochemical recurrence at high risk for metastasis. PARP Inhibitors In May the FDA approved olaparib (Lynparza) with abiraterone and prednisone (or prednisolone) for adult patients with deleterious or suspected deleterious BRCA-mutated mCRPC, as determined by an FDA- approved companion diagnostic test. In June the FDA approved talazoparib (Talzenna) with enzalutamide for homologous recombination repair (HRR) gene-mutated mCRPC.
2
Made with FlippingBook flipbook maker